Prolor Biotech
Subscribe to Newsletter
Home
About PROLOR Biotech
Board of Directors
Phillip Frost, M.D. (Chairman)
Marian Gorecki, Ph.D.
Abraham Havron, Ph.D.
Jane Hsiao, Ph.D.
Steve Rubin, J.D.
Fuad Fares, D.Sc.
Shai Novik
Management Team
Abraham Havron, Ph.D. - Chief Executive Officer
Eyal Fima, Ph.D. - Chief Operating Officer
Fuad Fares, D.Sc. - Chief Scientific Officer
Shai Novik - President
Products
hGH-CTP: Human Growth Hormone
FVII-CTP: Factor VIIa
GLP-1 / Glucagon dual receptor agonist
Technologies
Attempts to Extend the Life
CTP Competitive Advantages
CTP Scientific Papers
About RevPEG
Intellectual Property
Facilities & Production
Clinical Trials
hGH-CTP Phase I Data
hGH-CTP Phase II Data
Merck's FSH-CTP European Marketing Approval
Merck's Phase III and II FSH-CTP trial
Partnering
The Therapeutic Proteins Industry
The Challenges of Developing New Drugs
The Advantage of Developing Biobetter Versions of Existing Drugs
Investor Relations
News
News
SEC Filings
Company Information
Contact
Financials
Quote
Charts
Historical Prices
Financials
Contact Us
Navigation
Subscribe
Search
News
OPKO Health To Acquire PROLOR Biotech
4/24/2013 2:00:00 AM
PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX
4/8/2013 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Methods for Decreasing Body Fat with hGH-CTP
3/5/2013 7:30:00 AM
Free Research Reports on ALB, PBTH, RATE and WFR Issued by the Bedford Report
2/14/2013 8:15:00 AM
PROLOR Biotech's Longer-acting Human Growth Hormone Receives Orphan Drug Designation in Europe
2/13/2013 7:30:00 AM
PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
2/6/2013 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Broad Applications of its CTP Platform for Long Acting Therapeutic Proteins
1/7/2013 7:30:00 AM
PROLOR Biotech To Present At Oppenheimer 23rd Annual Healthcare Conference
12/10/2012 7:30:00 AM
PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
12/7/2012 7:30:00 AM
New Patent Covering PROLOR's Reversible-Pegylation Platform Technology is Allowed by U.S. Patent Office
11/13/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At Congress Of The GRS And IGF Society
10/18/2012 7:30:00 AM
PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology
10/16/2012 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent for Its Long-Acting Human Growth Hormone
10/3/2012 7:30:00 AM
PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
9/21/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
9/13/2012 7:40:00 AM
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
7/10/2012 7:30:00 AM
PROLOR Biotech To Present Data On Its Long-Acting Clotting Factors At Leading International Scientific Conference
6/29/2012 7:30:00 AM
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
6/26/2012 7:30:00 AM
PROLOR Biotech to Present at Jefferies 2012 Global Health Care Conference
5/30/2012 7:30:00 AM
PROLOR Biotech Announces Closing Of Underwritten Public Offering And Exercise Of Underwriters' Overallotment Option
5/16/2012 9:56:00 AM
PROLOR Biotech Announces Pricing of Public Offering of Common Stock
5/11/2012 8:46:00 AM
PROLOR Biotech Announces Proposed Public Offering Of Common Stock
5/10/2012 4:17:00 PM
PROLOR Biotech Announces Top-Line Results from Four-Month Treatment Extension of its Long-Acting Human Growth Hormone Phase II Trial
5/7/2012 8:00:00 AM
PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
4/20/2012 4:30:00 PM
PROLOR Biotech Announces Positive Results of Its Obesity/Diabetes Drug Candidate in Preclinical Weight Loss Study
4/17/2012 7:30:00 AM
PROLOR Biotech Initiates Phase II Trial of its Long-Acting Human Growth Hormone in Children with Growth Hormone Deficiency
3/20/2012 7:30:00 AM
PROLOR Biotech to Present Preclinical Data on Its Long-Acting Clotting Factors VIIa and IX at European Hemophilia Conference
2/23/2012 7:30:00 AM
PROLOR Biotech to Present at 2012 Citi Global Health Care Conference
2/22/2012 7:30:00 AM
PROLOR Biotech Announces Positive Preclinical Results from Comparative Study of its Long-Acting Clotting Factor VIIa
2/14/2012 7:30:00 AM
PROLOR Biotech Announces Positive Top-Line Results From Pilot Study of Its Long-Acting Human Growth Hormone Injected Twice Per Month
1/18/2012 7:30:00 AM
PROLOR Biotech to Present at Oppenheimer 22nd Annual Healthcare Conference
12/7/2011 7:30:00 AM
PROLOR Biotech to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11/8/2011 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering its Longer-Acting CTP-Modified Interferons
10/11/2011 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance for New U.S. Patent Covering Production and Manufacturing Processes for its Long-acting Human Growth Hormone
10/3/2011 7:30:00 AM
PROLOR Biotech to Present at Jefferies 2011 Global Healthcare Conference
9/21/2011 7:30:00 AM
Stock Information
Symbol: PBTH
Prolor Biotech, Inc.
Last Price
6.43
Change
-0.01
Bid
N/A
Ask
N/A
High
6.50
Low
4:00pm -
6.43
Volume
165038
Last Update
5/22/2013 10:27:36 PM
Media
A Video Overview of PROLOR Biotech
Video Interview with Shai Novik, President of PROLOR Biotech